Advances in hematopoietic cell transplantation (HCT) have led to an increasing number of transplant survivors. However, long-term survival is challenged by late relapse, late complications and late non-relapse mortality, and HCT survivors need continued lifelong surveillance for screening, early detection and timely treatment of late complications such as secondary cancers, late infections and organ toxicity. Guidelines for screening and preventive practices for pediatric and adult survivors of autologous and allogeneic HCT were updated and published in 2012. However, several barriers to the care of HCT survivors and routine utilization of these guidelines in clinical practice exist. Examples include paucity of and challenges to conducting prospective randomized trials for screening and prevention of late complications, lack of resources to manage late effects at the level of transplant centers and community health care providers, and inadequate tools to facilitate care and followup of HCT survivors. We summarize the longterm followup guidelines in this review, discuss ways that providers can integrate and utilize them for the care of their patients, and identify areas for research that can inform and increase the utilization of screening and prevention guidelines in clinical practice. Keywords: hematopoietic cell transplantation; long-term survival; late complications; screening; preventive practices INTRODUCTION Several advances in transplantation techniques and supportive care practices over the last four decades have improved long-term survival of patients undergoing autologous or allogeneic hematopoietic cell transplantation (HCT). As patients survive longer, there is an increasing recognition that pre-, peri-and posttransplant exposures have the potential to compromise life expectancy and can contribute to development of late complications. These complications can cause substantial morbidity and mortality and can impair quality of life among HCT survivors. This review will summarize the contemporary literature on long-term survival after autologous and allogeneic HCT and the recently updated guidelines for long-term followup of HCT survivors.
INTRODUCTION
Several advances in transplantation techniques and supportive care practices over the last four decades have improved long-term survival of patients undergoing autologous or allogeneic hematopoietic cell transplantation (HCT). As patients survive longer, there is an increasing recognition that pre-, peri-and posttransplant exposures have the potential to compromise life expectancy and can contribute to development of late complications. These complications can cause substantial morbidity and mortality and can impair quality of life among HCT survivors. This review will summarize the contemporary literature on long-term survival after autologous and allogeneic HCT and the recently updated guidelines for long-term followup of HCT survivors. [1] [2] [3] Specific late complications and the impact of late complications on quality of life for HCT recipients have been reviewed comprehensively elsewhere. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] We also discuss barriers and challenges to followup of survivors and implementation of screening and prevention guidelines, and identify areas for future research that can facilitate the long-term care of HCT recipients. Table 1 describes relatively recent large studies that have investigated long-term survival rates following HCT. As disease relapse is the predominant cause of mortality in the first 1-2 years after HCT, studies have generally included patients who are alive and disease-free at 2-5 years after transplantation in order to attempt to isolate the effects of HCT and other treatments on late complications and long-term outcomes. Many studies have also compared the survival of HCT recipients to that of general population controls. Studies vary with respect to methodology, and time horizon, diagnoses and transplant types considered. However, common themes include: (1) a high probability of longterm survival among patients who survive in remission for 2-5 years post transplantation, (2) life expectancy of HCT survivors continues to lag behind that of their age-and gender-matched peers from the general population for at least 15-20 years after HCT, (3) disease recurrence, chronic GVHD, organ failure and secondary cancers are common causes of late deaths and (4) chronic GVHD is an important factor associated with late mortality in allogeneic HCT recipients.
LONG-TERM SURVIVAL AFTER HCT
The Center for International Blood and Marrow Transplant Research (CIBMTR) recently published a large study that highlights these general observations. 15 Our analysis included 10 632 patients who were alive and disease free 2 years after receiving a myeloablative allogeneic HCT for ALL, AML, lymphoma, myelodysplastic syndromes or severe aplastic anemia. The median followup was 9 years, and 3788 patients had been observed for 10 years or more after transplantation. The probabilities of OS at 10 years after HCT were 80% for ALL, 84% for AML, 84% for lymphoma, 80% for myelodysplastic syndromes and 92% for severe aplastic anemia. The cumulative incidences of non-relapse mortality at 10 years ranged from 9-12% for these diseases. Despite being in remission for 2 years, recurrent disease was the most common cause of late deaths among patients with malignant disorders (41% of all deaths), especially during 2-5 years after HCT. Other frequent causes of death included chronic GVHD, infections, organ failure and secondary cancers. Older age at transplantation and chronic GVHD were two of the main drivers of overall and non-relapse mortality for all diseases studied. Compared to patients with no chronic GVHD, those with a history of chronic GVHD had significantly higher risks of non-relapse mortality (relative risks ranged from 2.28-4.23). The relative mortality rates were higher compared with general population matched for gender, age and nationality beginning at 2 years after HCT. Although the relative mortality rates declined over time for all diseases, they did not return to expected general population rates through 15 years post transplantation, emphasizing the need for prolonged followup of HCT survivors to prevent, identify and treat late complications, and optimize long-term survival.
Secondary cancers, late infections and organ-specific complications (for example, cardiovascular complications, end-stage renal disease and bronchiolitis obliterans) contribute to late non-relapse mortality among transplant survivors. Other complications (for example, dry eyes, xerostomia, avascular necrosis) may not directly have an impact on mortality, but can impair quality of life. Pre-, peri-and post-transplant exposures mediate specific late complications. For instance, chronic GVHD and its treatment (for example, corticosteroids) increase risks for late infections, ocular complications (for example, cataracts, dry eyes), oral complications (for example, xerostomia), genitourinary (for example, vaginal stenosis), metabolic complications (for example, metabolic syndrome, diabetes) and musculoskeletal complications (for example, osteoporosis, avascular necrosis). Patients with chronic GVHD have higher risks of secondary squamous cell cancers of the oropharyngeal tract, skin and genital area, whereas recipients of TBR have higher incidence of non-squamous cell cancers (for example, breast cancer).
GUIDELINES FOR LONG-TERM FOLLOWUP OF HCT RECIPIENTS
Recognizing the need for appropriate systematic long-term followup of autologous and allogeneic HCT survivors, consensus recommendations for screening and preventive practices were developed and published in 2006. 16, 17 An international group of experts was reconvened in 2011 to review and incorporate the best evidence available on late complications of HCT, and update the long-term followup guidelines. The updated guidelines were published in March 2012, [1] [2] [3] and can be accessed at www.BeTheMatch.org/md-guidelines (print version and app version for smart phones). A patient friendly version of the guidelines has also been developed by the National Marrow Donor Program and is available at www.BeTheMatch.org/Patient.
The guidelines have taken a pragmatic approach to the long-term followup of HCT survivors. Recommendations are organized by organ system and important followup issues (for example, psychosocial issues, fertility, general-health maintenance, secondary cancers). More common late complications are addressed and followup recommendations are presented in a way that can be quickly reviewed and implemented by a practicing clinician. The working group recognized the lack of high quality studies to guide recommendations. Where literature was lacking, recommendations were based on the general supposition that early diagnosis of complications may lead to early interventions and treatment.
The updated 2012 guidelines provide a greater emphasis on exposures and risk factors versus type of transplantation (autologous versus allogeneic). Specific enhancements in the updated guidelines include: (1) greater representation of experts from national transplant societies to increase the international applicability of the guidelines. In addition to the consensus guidelines described above, a framework for late effects screening and management guidelines with a specific pediatric HCT focus has been recently proposed. 20 Although there are many similarities, the latter take into account pre-and post-transplant exposures and late complications that are particularly relevant for pediatric HCT survivors. The Children's Oncology Group has also developed followup guidelines for pediatric cancer survivors that have sections relevant for HCT survivors (available at www.survivorshipguidelines.org). Table 2 highlights selected relatively common late complications that can occur in HCT survivors. Table 3 lists a summary of the long-term followup recommendations that are included in the updated 2012 guidelines.
SCREENING AND PREVENTION OF LATE COMPLICATIONS

CARE OF HCT SURVIVORS
The long-term followup of HCT survivors can present several challenges (Table 4) . Patients may not be aware of their exposures, risks and risk factors for specific late complications. As they survive longer after transplantation, the risks of relapse diminish over time and they are often referred to as 'cured' of their underlying disease-this may lead them to underappreciate the importance and need for continued surveillance for late effects. Furthermore, other patient factors such as distance from transplant center, accessibility to specialists and other health care providers, socioeconomic status, and health insurance coverage may present barriers to obtaining appropriate followup care. Transplant centers may lack the resources, infrastructure and expertise to provide ongoing followup for transplant survivors and for screening, preventing and treating late effects. Similarly, community healthcare providers (for example, primary care physicians and hematologists-oncologists) are often unaware of HCT-related exposures, their late consequences, and may lack expertise in managing the complex health care issues that can occur in transplant survivors.
The care of HCT survivors requires a multidisciplinary approach that incorporates the expertise and resources of transplant centers, referring hematologists-oncologists, primary care physicians and other health care providers. Such models of care will be increasingly relevant as centers try to meet the demand to perform more transplants for patients with life-threatening illnesses while balancing the care of long-term survivors. Nontransplant health-care providers will have a greater role in survivorship care, and may need to be aware of the unique exposures, risk factors and medical issues these patients face. Providers should integrate and involve their patients in this process, and ensure that they understand their risks and the surveillance required to prevent late complications. Although a template specific to HCT recipients is not available, a survivorshipcare plan that includes a treatment summary and a followup care plan may facilitate transition of HCT recipients from early posttransplant phase to survivor phase. This planning tool can serve as an instrument for reminding providers about appropriate surveillance for late complications based on an individual patient's risk factors and exposures. In addition, transplant centers and providers can consider incorporating the physician and patient versions of the long-term followup and preventive practices guidelines into a survivorship-care plan document for HCT recipients. To facilitate this, materials have been developed and are available free of charge in print, as a smart phone app, and online at www.BeTheMatch.org/md-guidelines (for physicians) and www.BeTheMatch.org/Patient (for patients).
AREAS FOR FUTURE RESEARCH
A number of areas pertaining to late complications and long-term followup of HCT survivors warrant further investigation. Institutional and registry (for example, CIBMTR) studies over the past decade have greatly increased our knowledge about the incidence, prevalence and risk factors for late effects after HCT. However, more research is needed on the etiology, degree of exposure and pathophysiology of these complications. There has been an increasing interest in investigating the role of genetic predisposition, and genetic and molecular factors in the pathogenesis of late complications. One such example is development of secondary cancers in HCT survivors, where mechanisms such as DNA double-strand-break-induced gene translocations, genomic instability owing to loss of DNA repair, and presence of inherited genetic polymorphisms have been described as having a role in their carcinogenesis. 15 The field of transplantation has evolved and progressed with a number of major advances in transplant treatments and supportive care. As late effects take time to manifest, our current understanding of their epidemiology reflects transplant practices prevalent between 5 and 20 years before studies were performed. Importantly, newer techniques are in some part responsive to the avoidance of late complications (for example, using non-TBI regimens in pediatric recipients to reduce risks of secondary cancers). The impact, incidence and risk factors for late complications from newer transplant techniques are not known and have to be studied (for example, non-myeloablative and reducedintensity conditioning regimens, non-TBI regimens, umbilical cord blood and haploidentical donor sources).
More work also needs to be done on understanding the best models of long-term care for HCT survivors, and their transition from transplant centers to the community. With the increasing demand for HCT, transplant centers frequently have to divert their limited resources towards extending HCT to a larger number of recipients, and providing immediate care for recipients in the pri-transplant time period. They may lack the interest and resources to take care of the long-term HCT survivors (especially patients without GVHD), and may consider this less important than making more transplants available to those who can benefit. Research can inform optimal care models that involve community health-care providers including non-physician providers (for example, nurse practitioners, physician assistants) in the care of HCT survivors. Efficient methods to train non-transplant physician and non-physician providers about transplant complications and followup also need evaluation. The economic impact of transplant survivorship on patients, centers and society needs to be investigated. Research is also needed on the implementation, dissemination and utilization of followup guidelines among patients and their providers. This will also facilitate future revisions to the guidelines and will prevent underscreening or overscreening for late complications. Of note, no randomized controlled trial has been conducted to demonstrate that increased surveillance and early detection of late complications leads to improved outcomes. More research into the effects of transplant survivorship on caregivers and families is also needed.
The Institute of Medicine (IOM) published a report in 2005 suggesting the importance of integrating the patient into their survivorship care through treatment summaries and care plans. 21 Several specific recommendations were made to: raise awareness among patients and providers, develop and use systematic evidence-based tools and guidelines for screening, develop quality measures for survivorship, support and develop new models of care coordination for survivors, educate health care providers, ensure access to affordable care and recognize survivorship care as an essential benefit in payment policies, and expand research. Despite these recommendations in a highprofile report, implementation of many of the recommendations has been very slow at best. Conclusively demonstrating, through well-defined studies, that recommendations such as those made by the IOM substantially improve outcomes for cancer patients and HCT recipients is likely to improve their uptake and implementation. Understanding and addressing the limitations to implementation of the recommendations from the 'Lost in Transition' report may be an important topic for a future IOM report.
The Working Group that updated and published the 2012 guidelines for screening and prevention of HCT late effects recognized that many recommendations were based on expert consensus opinion. In fact, there has been little increase in highlevel evidence to support screening practices since the initial publication in 2006. A need for more prospective studies and randomized clinical trials to guide development of evidencebased guidelines in the future was identified. A better understanding of barriers and facilitators to implementation of the guidelines in routine clinical practice is needed. Research is needed to increase awareness of the guidelines and to guide methods that can facilitate their utilization by transplant centers, community health care providers and patients.
While recognizing the need for more research, challenges to studying late effects of HCT have to be acknowledged. Owing to their rarity and the long latency period for development of late complications, randomized clinical trials are usually not feasible or very difficult and expensive to conduct. Outcomes registries have been an important resource to define the incidence and risk factors for HCT late effects. However, some limitations of registry studies have to be kept in mind. Given resource constraints for reporting and managing data, comprehensive information on the nature and severity of complications may not be available. Patients may no longer be under the care of their transplant center when they develop a late complication, and these data may not be reported. Details may not be available for pre-transplant exposures and on post-transplant exposures that are not captured by the registry. Therefore, outcomes-registry studies very likely underestimate the true incidence of late complications. Furthermore, exposures that can be evaluated as risk factors for late complications are limited to those captured by the outcomes registries.
To overcome some of these challenges, we need to consider some innovative approaches to research late complications of HCT and the care of HCT survivors. Novel research and analytic methods have to be evaluated, and to this effect, collaborations have to be fostered with our colleagues and experts in cancer control, prevention and non-transplant cancer survivorship. Registries and cooperative clinical trial groups, notwithstanding the challenges, should also focus on conducting prospective longterm studies and clinical trials on screening, prevention and management of late complications. Finally, partnerships among transplant centers, and between transplant centers and community healthcare providers should be developed to facilitate research that can ultimately have an impact on practice and policy for care of the HCT survivors. 
